Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd. (URGN)
By Gainey McKenna & Egleston Published [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year]
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired UroGen Pharma Ltd. ('EuroGen' or the 'Company') (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, both dates inclusive (the 'Class Period').
The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (i) UroGen's ENVISION clinical study for UGN-102 was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it lacked a concurrent control arm; (ii) as a result, UroGen would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (iii) UroGen failed to heed the U.S. Food and Drug Administration's ('FDA') warnings about the study design used to support a new drug application ('NDA') for UGN-102; and (iv) as a result, there was a substantial risk that the NDA for UGN-102 would not be approved.
Investors who purchased or otherwise acquired shares of EuroGen should contact the Firm prior to the July 28, 2025 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .
Please visit our website at http://www.gme-law.com for more information about the firm.
The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world's population sees AP journalism every day.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Truist Financial Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Kymera Therapeutics (KYMR – Research Report), with a price target of $53.00. Confident Investing Starts Here: According to TipRanks, Devarakonda is an analyst with an average return of -5.9% and a 32.60% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Cytokinetics, Regeneron, and Scholar Rock Holding. In addition to Truist Financial, Kymera Therapeutics also received a Buy from Citi's Geoff Meacham in a report issued today. However, yesterday, Morgan Stanley maintained a Hold rating on Kymera Therapeutics (NASDAQ: KYMR). Based on Kymera Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $22.1 million and a GAAP net loss of $65.58 million. In comparison, last year the company earned a revenue of $10.29 million and had a GAAP net loss of $48.56 million Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KYMR in relation to earlier this year. Most recently, in March 2025, Jeremy Chadwick, the COO of KYMR sold 1,383.00 shares for a total of $42,103.92.
Business Insider
an hour ago
- Business Insider
Blueprint Medicines (BPMC) was downgraded to a Hold Rating at TD Cowen
TD Cowen analyst Marc Frahm downgraded Blueprint Medicines (BPMC – Research Report) to a Hold today and set a price target of $130.00. Confident Investing Starts Here: Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Inozyme Pharma, and Xilio Therapeutics. According to TipRanks, Frahm has an average return of 3.7% and a 39.53% success rate on recommended stocks. In addition to TD Cowen, Blueprint Medicines also received a Hold from J.P. Morgan's Brian Cheng in a report issued today. However, on the same day, Citi reiterated a Sell rating on Blueprint Medicines (NASDAQ: BPMC). The company has a one-year high of $121.90 and a one-year low of $73.04. Currently, Blueprint Medicines has an average volume of 988.3K. Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Most recently, in March 2025, Jeffrey Albers, a Director at BPMC sold 5,766.00 shares for a total of $512,020.80.
Yahoo
2 hours ago
- Yahoo
Silicon Labs and Wirepas Surpass 10 Million Chipsets, Powering Industrial IoT at Scale
AUSTIN, Texas and TAMPERE, Finland, June 3, 2025 /PRNewswire/ -- Silicon Labs (NASDAQ: SLAB), the leading innovator in low-power wireless solutions, and Wirepas, a global leader in decentralized IoT connectivity, today announced they have shipped 10 million wireless SoCs running Wirepas' RF mesh connectivity software, primarily in the Indian market with the Silicon Labs sub-GHz FG23 SoC. These chips power some of the world's largest and most demanding industrial mesh networks across sectors including smart electricity metering, emergency lighting, industrial monitoring and building automation. The two companies have a long history of collaboration enabling robust, ultra-resilient and massively scalable IoT networks that meet the scale, security, and reliability demands of industrial-grade applications. This milestone confirms that their joint solution is not just technically sound, it is market-proven at scale, and ready to support the digital backbone of global infrastructure. In December 2024, Silicon Labs and Wirepas announced that four million smart electric meters using Wirepas Mesh software had been deployed in India built on the sub-GHz FG13 and FG23 platforms, helping the country meet the goals of its Advanced Metering Initiative. The solution provides reliable, cost-effective connectivity across dense, complex environments, being a critical enabler for India's ambitious grid modernization and electrification goals. Another standout success is in Norway, where more than one million similarly-equipped smart meters are connected in a single decentralized mesh network, one of the largest of its kind in the world. These types of deployments demonstrate that robust, self-healing mesh connectivity can now support national-scale infrastructure, laying the groundwork for smarter, more efficient, and more sustainable infrastructure powering cities and industries. Other segments are also gaining momentum, with some, such as the emergency lighting sector, experiencing very high adoption rates. "Our partnership with Wirepas is built on a shared vision: to enable industrial-grade wireless connectivity at scale," said Ross Sabolcik, Senior Vice President of Product Lines at Silicon Labs. "By combining Silicon Labs' energy-efficient wireless platforms with Wirepas' decentralized mesh stack, we help our customers build massive, secure, and resilient IoT networks faster and more cost-effectively. We're excited to continue driving transformation across industries together." "This 10-million milestone demonstrates the unmatched scalability and resilience of our joint solution," said Teppo Hemiä, CEO of Wirepas. "With Silicon Labs' hardware and our mesh software, we've enabled massive networks that simply work, even in the most challenging conditions. Our partnership is helping industries solve real problems at the infrastructure level, accelerating the digitalization and electrification of society." More information Read more about the collaboration between Silicon Labs and Wirepas to deliver smart meters to India, here and here. Learn more about how Silicon Labs and Wirepas are collaborating on the 2.4 GHz spectrum, here. See more features of the FG23 wireless SoC, here. About Silicon LabsAbout Silicon Labs Silicon Labs (NASDAQ: SLAB) is the leading innovator in low-power wireless connectivity, building embedded technology that connects devices and improves lives. Merging cutting-edge technology into the world's most highly integrated SoCs, Silicon Labs provides device makers with the solutions, support, and ecosystems needed to create advanced edge connectivity applications. Headquartered in Austin, Texas, Silicon Labs has operations in over 16 countries and is the trusted partner for innovative solutions in the smart home, industrial IoT, and smart cities markets. Learn more at About WirepasWirepas is a global leader in IoT connectivity, providing ultra-resilient, infinitely scalable mesh networks for large-scale industrial and commercial deployments. Its technology connects millions of devices worldwide, including the largest network of more than a million smart electricity meters. With proven 99.99% reliability and a team of deep experts guiding projects from planning to maintenance, Wirepas ensures unmatched business continuity. Wirepas is also the main contributor to and first implementor of the first non-cellular 5G standard NR+, purpose-built for massive IoT and using a free global spectrum. Wirepas operates globally across smart tracking, smart building and smart metering sectors. Learn more on View original content to download multimedia: SOURCE Silicon Labs
